Biocept Announces Clinical Validation and Commercial Launch of its Target Selector(TM) Multi-Gene Liquid Biopsy Panel for Lung Cancer

Stock Information for Biocept Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biocept Inc.

Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing
Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location
Data Affirming Biocept's Target Selector(TM) Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector(TM) BRAF Kit for Clients' Use in Their Own Laboratories
Biocept Reports First Quarter 2020 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.